- Cancer research
- Career spotlights
- Current events
- Customer stories
- Gene editing
- A faster path to analysis for mAbs as therapeutic agents
- Gene therapy takes a step forward
- ICELL8 technology keeps cardiovascular research pumping
- Women's Networking Event at AGBT 2020
- Detecting infectious disease threats in a changing climate
- Unraveling the world of microorganisms
- Microbiomes in the brain and belly
- Gaining insight into pulmonary arterial hypertension with purified exosomes
- Total RNA-seq from human biofluids and EVs
- Seq-ing the small
- Taking the SMARTer approach to RNA-seq of FFPE tissues
- Single-cell analysis
- Stem cell research
- Tips and troubleshooting
- That's Good Support!
- About our blog
Gene therapy takes a step forward
In the race to develop gene therapies to treat both common and rare genetic diseases, adeno-associated virus (AAV) vectors have very quickly become one of the top choices for in vivo gene delivery platforms (Goswami et al. 2019). AAV vectors are considered safe because of their low immunogenicity and cytotoxicity, ability to transduce nondividing cells, and very low frequency of integration into the host genome. Additionally, several recombinant and engineered AAVs have different serotypes that allow specific cell types to be targeted, including both dividing and nondividing cell types. The safety and efficacy of recombinant AAV vectors have been established in a number of Phase I, II, and III clinical trials.
To date, there are only two AAV-delivered gene therapies approved by the FDA. The first, Luxturna, was approved in 2017 for the treatment of Leber's congenital amaurosis, an inherited retinal disease. The second, Zolgensma, was approved just last year for the treatment of pediatric patients with spinal muscular atrophy. In addition to these two approved therapies, several other AAV therapies have been and are being evaluated in clinical trials worldwide.
One such therapy that has shown promise is AAV-mediated delivery of the dopa decarboxylase gene (DDC), which encodes the aromatic l-amino acid decarboxylase (AADC) enzyme. AADC deficiency is a rare neuromuscular disorder that is caused by mutations in the DDC gene that impair the enzyme's activity and lead to developmental delays and motor dysfunction. AADC deficiency manifests in early infancy, and, in severe cases, leaves patients bedridden for life. In their recent publication, Kojima et al. at Jichi Medical University described the results of a Phase I/II trial to investigate the effects of this AAV therapy on patients 4–19 years of age, with various DDC gene mutations. They administered a clinical-grade AAV vector expressing the human DDC gene via bilateral intraputaminal infusion to 6 patients, 5 of whom were bedridden. Following infusion, the authors monitored the patients' motor, cognitive, and verbal functions, as well as any adverse events caused by the AAV vector.
The authors found that motor function improved for all 6 patients, as indicated by increased Alberta Infant Motor Scale (AIMS) scores (Figure 1). Following treatment, one bedridden patient was able to walk with the assistance of a walker, and two others were able to stand with support. Other symptoms associated with AADC deficiency also showed improvement in all patients, including dystonia, hypersalivation, difficulty breathing, and emotional disturbances. No severe adverse events were observed, suggesting that this AAV-mediated gene therapy may be a safe and effective treatment for patients with AADC deficiency.
This study demonstrates the potential of AAV therapies for treating rare genetic diseases like AADC deficiency. It also demonstrates the importance of having a reliable partner who can manufacture clinical-grade AAV vectors to administer to patients for clinical studies. We are proud that Kojima et al. chose Takara Bio as their manufacturing partner for this study.
Goswami, R. et al., Gene therapy leaves a vicious cycle. Front. Oncol. 9, doi: 10.3389/fonc.2019.00297.
Kojima, K. et al., Gene therapy improves motor and mental function of aromatic L-amino acid decarboxylase deficiency. Brain 42, 322–333 (2019).
Back to Blog Front
Takara Bio USA, Inc.
United States/Canada: +1.800.662.2566 • Asia Pacific: +1.650.919.7300 • Europe: +33.(0)1.3904.6880 • Japan: +81.(0)77.565.6999
FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES. © 2020 Takara Bio Inc. All Rights Reserved. All trademarks are the property of Takara Bio Inc. or its affiliate(s) in the U.S. and/or other countries or their respective owners. Certain trademarks may not be registered in all jurisdictions. Additional product, intellectual property, and restricted use information is available at takarabio.com.